Encouraging pancreas SBRT data from MASTERPLAN. Adding 40 Gy/5 fx cut 12mo locoregional recurrence from 52% to 20% (P=.022). OS 22 vs 14mo, but this is a 74-pt phase II with mixed resectability. Promising; not definitive OS evidence. #ESMO26 #radonc https://t.co/V1L9O30kcB https://t.co/mQ9DiXp7qH